A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered With Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00519480
• Other study ID #: KG2110243
• Status: Completed
• Phase: Phase 1
• First received: August 20, 2007
• Last updated: September 1, 2017
• Start date: September 11, 2007
• Est. completion date: April 1, 2008

Study information

• Verified date: September 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess safety and tolerability of metformin plus GSK189075 in people with Type 2 Diabetes. About 48 people will participate in this study. Volunteers will not know if they are receiving GSK189075 or a placebo. Participation will last about 5 weeks including a run-in period of up to 2 weeks if necessary to increase metformin up to 2000mg daily, a 13-day treatment period, and a follow-up visit about 1 week after the treatment period. Volunteers will remain in the research clinic beginning 2 days before they receive the first dose of GSK189075 until after the morning dose on the fourth day and from the afternoon of the 12th day of dosing until the morning after the last dose. They will have clinic visits on dosing Days 6, 8, and 10. Volunteers will be given equipment and instructions for measuring their blood sugar at home and will be asked to keep a study diary. Blood pressure, heart rate, laboratory tests on blood and urine, physical examinations, reports of drug side effects and ECGs will be obtained during the clinic visits to assess safety.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: April 1, 2008
• Est. primary completion date: April 1, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 64 Years

Eligibility

Inclusion Criteria:

• Diagnosed with Type 2 Diabetes for at least three months prior to study

• Diabetes treated with metformin only

• Give consent and sign an informed consent form.

• Agree to follow specific requirements of birth control during participation.

Exclusion Criteria:

• Type I Diabetes.

• Treatment with insulin within 3 months prior to screening

• History of diabetic ketoacidosis or lactic acidosis

• Allergy or sensitivity to metformin or similar drugs or any medical conditions which prohibit metformin use

• Excessive blood donation 56 days before the start of the study

• Urinary tract or bladder infections within four weeks of study start

• Alcohol abuse or illicit drug use within 12 months of study start

• Receiving other investigational drugs or participating in other research trials within 30 of the study start

• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements with 7-14 days of study start

• Live alone without regular, daily interactions with someone who can be an emergency contact

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• GSK189075
GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
• Metformin
Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
• Placebo
Placebo will be available as an oral tablets.

Locations

Country	Name	City	State
Argentina	GSK Investigational Site	Buenos Aires
Germany	GSK Investigational Site	Berlin
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Argentina,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical laboratory tests, ECGs, physical exam & adverse events:		screening, in-clinic stays, outpatient clinic visits & follow up visit (approximately 50 days)
Primary	Home diary of blood sugar results, adverse events and drug dosing.		throughout the study (approximately 50 days)
Secondary	study drug blood levels:		Dosing Days 1 & 13 metformin blood levels: Days -1 & 13
Secondary	Blood glucose & insulin levels following oral glucose challenge:		Dosing Days -1 & 13
Secondary	fluid intake & output		dosing Days -1 - 3, 13

External Links

•   Results for study KG2110243 can be found on the GSK Clinical Study Register.